(Reuters) - ZURICH, July 26 - Swiss-based pharma firm Roche Holding AG said on Thursday the European Commission had approved its drug Mircera to treat anaemia associated with chronic kidney disease.
The potential blockbuster drug belongs to a class of medicines known as erythropoiesis-stimulating agents. They are used to boost red blood cells in anaemia patients to help avoid the need for blood transfusions.
Read more at Reuters.com Market News
The potential blockbuster drug belongs to a class of medicines known as erythropoiesis-stimulating agents. They are used to boost red blood cells in anaemia patients to help avoid the need for blood transfusions.
Read more at Reuters.com Market News
No comments:
Post a Comment